Uploaded August 2025 | Updated September 2026, 3 weeks ago
The potential of psychedelics to address unmet needs in mental health and beyond has captured the attention of regulators and policymakers worldwide. This presentation will address important challenges and developments in the EU. Examples: the European Medicines Agency Multi-Stakeholder Workshop on Psychedelics, which united regulators, academics, patient and clinician representatives, learned societies, and industry to discuss the medical development and application of psychedelics ; the first EU-funded multi-site trial of psychedelics, PsyPal, which will test the potential of psilocybin to alleviate psychological distress in patients with chronic, life-limiting conditions, alongside key multidisciplinary collaborations to support the development of psychedelic therapies.
Bio:
A neuroscientist by training, Francisca is deeply passionate about people, the brain and health. In her interdisciplinary academic path, including a dual MSc in Brain and Mind Sciences from University College London (UCL) and Sorbonne Université and a BSc from the Maastricht Science Programme, she delved into various fields of interest, such as molecular biology, neuropsychopharmacology and clinical neurology and neuropsychiatry, and developed a keen appreciation for effective science communication. Her desire to contribute to the translation of science into better care for those in need initially led to her involvement in psychedelics-related initiatives at the European Medicines Agency (EMA), notably the EMA Multi-Stakeholder Workshop on Psychedelics held in April 2024.
The potential of psychedelics to address unmet needs in mental health and beyond has captured the attention of regulators and policymakers worldwide. This presentation will address important challenges and developments in the EU. Examples: the European Medicines Agency Multi-Stakeholder Workshop on Psychedelics, which united regulators, academics, patient and clinician representatives, learned societies, and industry to discuss the medical development and application of psychedelics ; the first EU-funded multi-site trial of psychedelics, PsyPal, which will test the potential of psilocybin to alleviate psychological distress in patients with chronic, life-limiting conditions, alongside key multidisciplinary collaborations to support the development of psychedelic therapies.
Bio:
A neuroscientist by training, Francisca is deeply passionate about people, the brain and health. In her interdisciplinary academic path, including a dual MSc in Brain and Mind Sciences from University College London (UCL) and Sorbonne Université and a BSc from the Maastricht Science Programme, she delved into various fields of interest, such as molecular biology, neuropsychopharmacology and clinical neurology and neuropsychiatry, and developed a keen appreciation for effective science communication. Her desire to contribute to the translation of science into better care for those in need initially led to her involvement in psychedelics-related initiatives at the European Medicines Agency (EMA), notably the EMA Multi-Stakeholder Workshop on Psychedelics held in April 2024.
